Tumor Biology

, Volume 37, Issue 1, pp 773–779 | Cite as

RND1 is up-regulated in esophageal squamous cell carcinoma and promotes the growth and migration of cancer cells

Original Article


RND1 is reported to control the dynamics of cytoskeleton, cell growth, and survival, and dysregulation of RND1 is involved in the tumorigenesis. However, its expression and functions in the esophageal squamous cell carcinoma (ESCC) are unknown. In the present study, it was found that the expression of RND1 was up-regulated in ESCC tissues compared with the adjacent normal tissues. Forced expression of RND1 promoted the growth and migration of ESCC cells, while knocking down the expression of RND1 inhibited the growth, migration, and metastasis of ESCC cells. Molecular mechanism studies showed that RND1 activated ERK signaling. In summary, our study suggested that RND1 plays an important role in the progression of ESCC, and RND1 might be a promising target for the treatment of ESCC.


RND1 ESCC ERK signaling Cell growth and migration 


Conflict of interest



  1. 1.
    Duquette PM, Lamarche-Vane N. Rho GTPases in embryonic development. Small GTPases. 2012;5(2):8.Google Scholar
  2. 2.
    Matsuoka T, Yashiro M. Rho/ROCK signaling in motility and metastasis of gastric cancer. World J Gastroenterol. 2012;20(38):13756–66.CrossRefGoogle Scholar
  3. 3.
    Zuo Y, Oh W, Frost JA. Controlling the switches: Rho GTPase regulation during animal cell mitosis. Cell Signal. 2011;26(12):2998–3006.CrossRefGoogle Scholar
  4. 4.
    Chardin P. Rnd proteins: a new family of Rho-related proteins that interfere with the assembly of filamentous actin structures and cell adhesion. Prog Mol Subcell Biol. 1999;22:39–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Riou P, Villalonga P, Ridley AJ. Rnd proteins: multifunctional regulators of the cytoskeleton and cell cycle progression. Bioessays. 2011;32(11):986–92.CrossRefGoogle Scholar
  6. 6.
    Oinuma I, Kawada K, Tsukagoshi K, Negishi M. Rnd1 and Rnd3 targeting to lipid raft is required for p190 RhoGAP activation. Mol Biol Cell. 2011;23(8):1593–604.CrossRefGoogle Scholar
  7. 7.
    Goh LL, Manser E. The GTPase-deficient Rnd proteins are stabilized by their effectors. J Biol Chem. 2011;287(37):31311–20.CrossRefGoogle Scholar
  8. 8.
    Goh LL, Manser E. The RhoA GEF Syx is a target of Rnd3 and regulated via a Raf1-like ubiquitin-related domain. PLoS One. 2012;5(8), e12409.CrossRefGoogle Scholar
  9. 9.
    Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P. A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. J Cell Biol. 1998;141(1):187–97.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang Y, He H, Srivastava N, et al. Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. Sci Signal. 2011;5(207):ra6.Google Scholar
  11. 11.
    Li YH, Ghavampur S, Bondallaz P, Will L, Grenningloh G, Puschel AW. Rnd1 regulates axon extension by enhancing the microtubule destabilizing activity of SCG10. J Biol Chem. 2009;284(1):363–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Shen L, Qin K, Wang D, et al. Overexpression of Oct4 suppresses the metastatic potential of breast cancer cells via Rnd1 downregulation. Biochim Biophys Acta. 2014;1842(11):2087–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Okada T, Sinha S, Esposito I, et al. The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nat Cell Biol. 2014;17(1):81–94.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.CrossRefPubMedGoogle Scholar
  15. 15.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  16. 16.
    Yang Q, Luo GY, Li Y, Shan HB, Wang HY, Xu GL. Expression of Rac-1 related to tumor depth, lymph node metastasis and patient prognosis in esophageal squamous cell carcinoma. Med Oncol. 2012;30(4):689.CrossRefGoogle Scholar
  17. 17.
    Faried A, Faried LS, Kimura H, et al. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer. 2006;42(10):1455–65.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhao H, Yang J, Fan T, Li S, Ren X. RhoE functions as a tumor suppressor in esophageal squamous cell carcinoma and modulates the PTEN/PI3K/Akt signaling pathway. Tumour Biol. 2012;33(5):1363–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Fichter CD, Gudernatsch V, Przypadlo CM, et al. (2015) ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways. J Mol Med (Berl) (Epub ahead of print)Google Scholar
  20. 20.
    Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2010;13(12):928–42.CrossRefGoogle Scholar
  21. 21.
    Cui X, Li S, Li T, et al. Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2012;7(5):2382–91.Google Scholar
  22. 22.
    Liu H, Wang X, Shi G, Jiang L, Liu X. Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo. Tumour Biol. 2012;35(8):8249–58.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of thoracic surgeryShanghai Jiao Tong University Affiliated Sixth People’s HospitalShanghaiChina

Personalised recommendations